Complete responses were reported in more patients taking aprepitant in both the acute (76% vs 69%, p=0.034) and delayed (55% vs 49%, p=0.064) phases of vomiting although the delayed phase difference did not reach statistical significance because nausea was not as well controlled as vomiting in this phase.
← all excerpts
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant.
1
—
—